Market Cap 594.64M
Revenue (ttm) 85.21M
Net Income (ttm) -140.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -164.43%
Debt to Equity Ratio 0.00
Volume 717,100
Avg Vol 913,072
Day's Range N/A - N/A
Shares Out 52.28M
Stochastic %K 25%
Beta 2.70
Analysts Strong Sell
Price Target $28.50

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macu...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 505 2680
Address:
5858 Horton Street, Suite 455, EmeryVille, United States
BioRich
BioRich Jul. 21 at 4:42 PM
$FDMT continues to get attention. New to many so take a look and let me know your thoughts. $IBRX, $SMMT $SABS and $VKTX also leading the first half of the day. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more( money. Cheers!
0 · Reply
BioRich
BioRich Jul. 20 at 2:48 PM
$NUVB Great news. Leads my Bios this fine Monday morning along with $OTLK and $RGNX . Added $MIST as a hot pick leading into next earnings (early execution play) and $FDMT. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
Merlintrader
Merlintrader Jul. 19 at 2:10 PM
$FDMT ASRS 2026 Retina Showdown: New Data Put $FDMT, $RGNX and $KLRS Under the Spotlight https://www.merlintrader.com/asrs-2026-retina-showdown/
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 18 at 9:11 PM
$FDMT Headline here today. 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population "today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) population. The data were presented by Carl Awh, M.D."
0 · Reply
ajmrtxl
ajmrtxl Jul. 17 at 4:13 PM
$FDMT 's latest data on SqueezeFinder
0 · Reply
G101SPM
G101SPM Jul. 16 at 7:10 PM
#SHOWTIME merican Society of Retina Specialists Meeting (July 17) Scheduled to appear: $FDMT, $KLRS, $OCGN
0 · Reply
Xxxxcccemre
Xxxxcccemre Jul. 15 at 9:51 PM
$FDMT I haven’t been here for a while , looking for re entry when are the next upcoming catalysts ?
0 · Reply
ajmrtxl
ajmrtxl Jul. 15 at 2:12 PM
$FDMT 's latest data on SqueezeFinder
0 · Reply
laaarsas
laaarsas Jul. 15 at 12:54 PM
$FDMT What people think here for 4FRONT?
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jul. 14 at 9:40 PM
$FDMT More insider sales.
1 · Reply
Latest News on FDMT
4DMT Announces New Employment Inducement Grants

Jul 17, 2026, 4:05 PM EDT - 5 days ago

4DMT Announces New Employment Inducement Grants


4D Molecular completes enrollment in 4FRONT-2 trial

2026-06-29T12:15:46.000Z - 23 days ago

4D Molecular completes enrollment in 4FRONT-2 trial


4D Molecular Therapeutics Transcript: AGM 2026

Jun 17, 2026, 1:30 PM EDT - 5 weeks ago

4D Molecular Therapeutics Transcript: AGM 2026


4DMT to Participate in Upcoming Investor Conferences

May 27, 2026, 8:00 AM EDT - 2 months ago

4DMT to Participate in Upcoming Investor Conferences


4D Molecular files $400M mixed securities shelf

2026-05-07T22:48:23.000Z - 2 months ago

4D Molecular files $400M mixed securities shelf


4D Molecular Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

4D Molecular Therapeutics Quarterly report: Q1 2026


4D Molecular Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

4D Molecular Therapeutics Earnings release: Q1 2026


4D Molecular Therapeutics Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 2 months ago

4D Molecular Therapeutics Slides: Corporate presentation


4D Molecular Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

4D Molecular Therapeutics Proxy statement: Proxy filing


4D Molecular Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

4D Molecular Therapeutics Proxy statement: Proxy filing


4D Molecular assumed with a Buy at Jefferies

2026-03-30T13:08:58.000Z - 4 months ago

4D Molecular assumed with a Buy at Jefferies


4D Molecular Therapeutics Annual report: Q4 2025

Mar 18, 2026, 5:00 PM EDT - 4 months ago

4D Molecular Therapeutics Annual report: Q4 2025


4D Molecular Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 5:00 PM EDT - 4 months ago

4D Molecular Therapeutics Earnings release: Q4 2025


4D Molecular Therapeutics Slides: Corporate presentation

Mar 18, 2026, 7:00 AM EDT - 4 months ago

4D Molecular Therapeutics Slides: Corporate presentation


4DMT to Participate in Upcoming Investor Meetings

Mar 16, 2026, 8:00 AM EDT - 4 months ago

4DMT to Participate in Upcoming Investor Meetings


4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial

2026-02-09T13:26:19.000Z - 5 months ago

4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial


4D Molecular assumed with an Overweight at Barclays

2026-01-27T21:27:44.000Z - 6 months ago

4D Molecular assumed with an Overweight at Barclays


4D Molecular announces employment inducement grants

2026-01-19T18:35:06.000Z - 6 months ago

4D Molecular announces employment inducement grants


4D Molecular Therapeutics Transcript: Study Result

Dec 17, 2025, 8:00 AM EST - 7 months ago

4D Molecular Therapeutics Transcript: Study Result


4D Molecular Therapeutics Press release: Study Result

Dec 17, 2025, 8:00 AM EST - 7 months ago

4D Molecular Therapeutics Press release: Study Result


4D Molecular Therapeutics Slides: Study Result

Dec 17, 2025, 8:00 AM EST - 7 months ago

4D Molecular Therapeutics Slides: Study Result


4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 8 months ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference


4D Molecular names Kristian Humer as CFO

2025-11-17T11:10:33.000Z - 8 months ago

4D Molecular names Kristian Humer as CFO


4DMT Appoints Kristian Humer as Chief Financial Officer

Nov 17, 2025, 6:00 AM EST - 8 months ago

4DMT Appoints Kristian Humer as Chief Financial Officer


4D Molecular price target raised to $32 from $26 at RBC Capital

2025-11-11T14:25:18.000Z - 9 months ago

4D Molecular price target raised to $32 from $26 at RBC Capital


4D Molecular price target lowered to $33 from $38 at Barclays

2025-11-11T10:25:26.000Z - 9 months ago

4D Molecular price target lowered to $33 from $38 at Barclays


4D Molecular Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

4D Molecular Therapeutics Quarterly report: Q3 2025


4D Molecular Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

4D Molecular Therapeutics Earnings release: Q3 2025


4D Molecular Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Quarterly report: Q2 2025


4D Molecular Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Earnings release: Q2 2025


4D Molecular Therapeutics Slides: FY 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025


4D Molecular Therapeutics Slides: FY 2025

May 14, 2025, 5:20 PM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025


4D Molecular Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

4D Molecular Therapeutics Earnings release: Q1 2025


4D Molecular Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

4D Molecular Therapeutics Quarterly report: Q1 2025


4D Molecular Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Proxy statement: Proxy Filing


4D Molecular Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Proxy statement: Proxy Filing


4D Molecular Therapeutics Slides: FY 2025

Mar 11, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025


4D Molecular Therapeutics Annual report: Q4 2024

Feb 28, 2025, 4:00 PM EST - 1 year ago

4D Molecular Therapeutics Annual report: Q4 2024


4D Molecular Therapeutics Earnings release: Q4 2024

Feb 28, 2025, 4:00 PM EST - 1 year ago

4D Molecular Therapeutics Earnings release: Q4 2024


4D Molecular Therapeutics Transcript: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Transcript: Study Result


4D Molecular Therapeutics Press release: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Press release: Study Result


4D Molecular Therapeutics Slides: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Slides: Study Result


4D Molecular Therapeutics Slides: FY 2024

Nov 19, 2024, 7:00 AM EST - 1 year ago

4D Molecular Therapeutics Slides: FY 2024


BioRich
BioRich Jul. 21 at 4:42 PM
$FDMT continues to get attention. New to many so take a look and let me know your thoughts. $IBRX, $SMMT $SABS and $VKTX also leading the first half of the day. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more( money. Cheers!
0 · Reply
BioRich
BioRich Jul. 20 at 2:48 PM
$NUVB Great news. Leads my Bios this fine Monday morning along with $OTLK and $RGNX . Added $MIST as a hot pick leading into next earnings (early execution play) and $FDMT. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
Merlintrader
Merlintrader Jul. 19 at 2:10 PM
$FDMT ASRS 2026 Retina Showdown: New Data Put $FDMT, $RGNX and $KLRS Under the Spotlight https://www.merlintrader.com/asrs-2026-retina-showdown/
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 18 at 9:11 PM
$FDMT Headline here today. 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population "today announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) population. The data were presented by Carl Awh, M.D."
0 · Reply
ajmrtxl
ajmrtxl Jul. 17 at 4:13 PM
$FDMT 's latest data on SqueezeFinder
0 · Reply
G101SPM
G101SPM Jul. 16 at 7:10 PM
#SHOWTIME merican Society of Retina Specialists Meeting (July 17) Scheduled to appear: $FDMT, $KLRS, $OCGN
0 · Reply
Xxxxcccemre
Xxxxcccemre Jul. 15 at 9:51 PM
$FDMT I haven’t been here for a while , looking for re entry when are the next upcoming catalysts ?
0 · Reply
ajmrtxl
ajmrtxl Jul. 15 at 2:12 PM
$FDMT 's latest data on SqueezeFinder
0 · Reply
laaarsas
laaarsas Jul. 15 at 12:54 PM
$FDMT What people think here for 4FRONT?
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jul. 14 at 9:40 PM
$FDMT More insider sales.
1 · Reply
BillionerOfKing
BillionerOfKing Jul. 9 at 12:44 AM
$FDMT Current Stock Price: $13.02 Contracts to trade: $13.0 FDMT Jul 17 2026 Call Entry: $0.73 Exit: $1.03 ROI: 42% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Helpmrwizard
Helpmrwizard Jul. 7 at 5:09 PM
$FDMT 👀
0 · Reply
LMARB
LMARB Jul. 1 at 3:19 PM
$FDMT wonder what this will avg after 2 year follow up presentation in 3 weeks
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 4:52 PM
$FDMT Got cute and swung one too many times...oh well. I'll take a long position once this cools off.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 4:04 PM
$FDMT RSI of 77? It's been a long time since it's seen that kind of strength.
0 · Reply
Doozio
Doozio Jun. 30 at 2:20 AM
$FDMT ENTA 🐒🍌🧠⏰♾️
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 12:04 AM
$FDMT https://www.statnews.com/2026/06/29/vijay-kumar-exits-fda-office-of-therapeutic-products/
1 · Reply
StonkMethod
StonkMethod Jun. 29 at 6:58 PM
0 · Reply
caronte
caronte Jun. 29 at 6:56 PM
$FDMT hi all, I was monitoring the up and dows to re-enter at a lower level (like 6-7) but apparently i did not time it well. Would you guys jump in at 13? On the long term I have no doubts, I believe in this company but in the short term (for a swing) it is damn hard to optimize timing. Thankyou and @ReturnOfEsquire how are you?
1 · Reply
Helpmrwizard
Helpmrwizard Jun. 29 at 4:54 PM
$FDMT looking interesting
0 · Reply
InvestorWisdom
InvestorWisdom Jun. 24 at 3:53 AM
$CMPS updated chart: It did not close under the 10ema for a couple months on the last run… and it has potentially regained it today. The low of the day was right on it after closing above 4 days ago… It might still be forming a base and need more time, but this could be the start of a new uptrend, cause IMO money is rotating into Biotech, which is one of the top near term sectors that will benefit significantly from the growth of AI… and many biotech stocks have been forming bottom and continuation bases = institutions accumulating  Compass has the potential to be a BIG one. The White House is pushing psychedelics and no one else is closer + Compass potential is massive and not fairly represented in this $1.7b valuation imo + Robert F Kennedy is pro psychedelics If they all want psychedelics approved for veterans etc it’s gonna get approved imo. There’s no significant side effects so what is the risk if it’s working with so many peeps?… and approval could happen as soon as this year I have already posted charts for $IOVA $AUPH $INSM $FDMT … heres 3 screenshots, i included XBI to show the sector base breakout + some key DD...
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 24 at 12:07 AM
$FDMT Huge insider sell announced. David Kirn sold 114,746 shares for $1,200,851.31. I'm sure Scott Bizily will be selling, too.
0 · Reply